Infliximab biosimilars to launch in the UK as innovator product reaches patent expiry

Biosimilar monoclonal antibody versions of Janssen Biologics’s Remicade — a medicine that contains infliximab and is used for a variety of inflammatory conditions — will be launched in the UK as patent protection for the innovator product comes to an end. Napp Pharmaceuticals will launch Remsima in the UK on 25 February 2015, after the patent for Remicade expires on 24 February 2015. Napp has the exclusive rights to distribute Remsima in the UK, although the marketing authorisation holder is Celltrion Healthcare Hungary. Remsina has already been launched in other European countries such as Norway, Portugal and Ireland, says a Napp spokesperson.

Read the source article at pharmaceutical-journal.com

About the Author

Leave a Reply